The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Evommune Inc shares valued at $17,350 were purchased by Hopfner Robert Lorne on Dec 19 ’25. At $17.35 per share, Hopfner Robert Lorne acquired 1,000 shares. The insider’s holdings grew to 4,026 shares worth approximately $65221.2 following the completion of this transaction.
As published in their initiating research note from H.C. Wainwright on January 06, 2026, Evommune Inc [EVMN] has been a Buy and the price target has been revised to $35. Analysts at William Blair started covering the stock with ‘”an Outperform”‘ outlook in a report released in early December. As of December 01, 2025, Morgan Stanley has initiated its “an Overweight” rating for EVMN. Earlier on December 01, 2025, Leerink Partners initiated its rating. Their recommendation was “an Outperform” for EVMN stock.
Analyzing EVMN Stock Performance
On last trading session, Evommune Inc [NYSE: EVMN] rose 0.75% to $16.2. The stock’s lowest price that day was $15.9, but it reached a high of $16.98 in the same session. During the last five days, there has been a drop of approximately -7.53%.
Support And Resistance Levels for Evommune Inc (EVMN)
According to the 24-hour chart, there is a support level at 15.74, which, if violated, would cause prices to drop to 15.27. In the upper region, resistance lies at 16.83. The next price resistance is at 17.45. RSI (Relative Strength Index) is 42.38 on the 14-day chart, showing neutral technical sentiment.
Is Evommune Inc subject to short interest?
Stocks of Evommune Inc saw a sharp rise in short interest on 2025-12-15 jumping by 0.38 million shares to 0.48 million. Data from Yahoo Finance shows that the short interest on 2025-11-14 was 0.1 million shares. A jump of 78.55% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 4.64 of the overall float, the days-to-cover ratio (short ratio) jumped to 4.64.
Which companies own the most shares of Evommune Inc (EVMN)?
In terms of Evommune Inc share price expectations, FactSet research, analysts set an average price target of 40 in the next 12 months, up nearly 148.76% from the previous closing price of $16.08. Analysts anticipate Evommune Inc stock to reach 42 by 2026, with the lowest price target being 35. On December 01, 2025, Evercore ISI assigned a price target of “an Outperform” to the stock and initiated coverage with a $40.
